As a urologic oncologist, I specialize in the surgical treatment of cancers involving the kidney, bladder, prostate, testis, and penis. My training as a Urologic Oncologist began at Temple University School Medicine where I received my medical degree and completed a Urology residency. Following completion of residency I received fellowship training in Urologic Oncology at the Mayo Clinic.
At University of Florida Health, I am an associate professor and also serve as the associate director for clinical research at the BOB体育 Cancer Center. My clinical interests focus on the surgical management of renal and bladder cancer, including radical cystectomy and minimally invasive techniques such as laparoscopic robotic cystectomy. While my practice focuses on the surgical management of urologic malignancies I place great emphasis on multidisciplinary cancer care involving medical and radiation oncologists. Administratively, I am an active member of the UFHealth Cancer Center and the leader of the Genitourinary Disease Site Group and the Chairman of the Scientific Review and Monitoring Committee.
My research interest is primarily related to improving the evaluation and treatment of patients presenting with genitourinary malignancies. To date, most of my research effort has focused on the management of bladder and kidney cancer. Additionally, I have a strong interest in involving appropriately selected patients in clinical trials which are designed to evaluate new treatment regimens and hopefully improve the care of patients at the University of Florida and beyond.
Bladder cancer is the 8th most common cancer in the BOB体育 Cancer Center catchment area and the 7th most common cancer presenting to UFHealth. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle鈥�
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as鈥�
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesJuly 13, 2023
The University of Florida Health Cancer Center has appointed two accomplished oncologists to key executive leadership roles, positioning the center to reach鈥�
Department of Urology, +4 more
Bladder cancer is the fourth most common cancer in men and eighth most common cancer in women, affecting about 80,000 people in the United States every year.鈥�
